🇺🇸 Prothionamide in United States

219 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 219

Most-reported reactions

1. Electrocardiogram Qt Prolonged — 30 reports (13.7%)
2. Hepatotoxicity — 30 reports (13.7%)
3. Vomiting — 30 reports (13.7%)
4. Arrhythmia — 20 reports (9.13%)
5. Neuropathy Peripheral — 20 reports (9.13%)
6. Anaemia — 19 reports (8.68%)
7. Drug Resistance — 19 reports (8.68%)
8. Nausea — 19 reports (8.68%)
9. Off Label Use — 18 reports (8.22%)
10. Alanine Aminotransferase Increased — 14 reports (6.39%)

Source database →

Frequently asked questions

Is Prothionamide approved in United States?

Prothionamide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Prothionamide in United States?

IUATLD, Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.